



## The Mouse Xenograft Model in Cancer Research

Guest Editor:

**Dr. Konstantinos Dimas**

Department of Pharmacology,  
University of Thessaly, Biopolis,  
41500 Larissa, Greece

Deadline for manuscript  
submissions:

**15 July 2024**

### Message from the Guest Editor

Dear Colleagues,

Human-to-mouse cancer xenografts are commonly used in cancer research to study the effectiveness of new treatments and to gain a better understanding of cancer biology.

Xenografts can be made from a wide range of human cancers, including breast, prostate, lung and colon cancers. They can also be used to study the effects of different cancer therapies, such as chemotherapy, radiotherapy and immunotherapy, in a living organism.

However, there are limitations to this technique. These models cannot recapitulate the complex interactions between tumour cells, stroma and the human immune system. In addition, the use of animal models raises ethical concerns, and there is an ongoing debate about the validity of using animal models to study human diseases.

In this context, this Special Issue aims to bring the attention of *Cancers* readers to advances, cutting-edge developments, expertise and know-how across all cancer types in regard to these valuable animal models of cancer. Thus, we cordially invite authors to submit original articles, reviews and opinions that highlight their potential as tools for basic, translational and even precision medicine.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

## Contact Us

---

Cancers Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)